European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy.
Paradise
Jordan
J
Institute for Science, Law and Technology, Chicago-Kent College of Law, Illinois Institute of Technology, Chicago, Ill., USA.
D035843:Biomedical Research / Q000331:legislation & jurisprudence; D001709:Biotechnology / Q000331:legislation & jurisprudence*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics*; D032821:Commodification; D005062:European Union; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D005826:Genetics, Medical / Q000266:history; D006297:Health Services Accessibility / Q000331:legislation & jurisprudence; D049673:History, 20th Century; D006801:Humans; D008004:Licensure / Q000331:legislation & jurisprudence; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D011785:Quality Assurance, Health Care / Q000331:legislation & jurisprudence; D014481:United States